HCC2157 (ATCC® CRL-2340)

Organism: Homo sapiens, human  /  Cell Type: Epithelial  /  Tissue: mammary gland; breast  /  Disease: TNM stage IIIA, grade 2,primary ductal carcinoma

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Tissue mammary gland; breast
Cell Type Epithelial
Product Format frozen
Morphology epithelial
Culture Properties suspension, multicell aggregates, Cells in suspension show an inclination to form duct-like structures and gland-like structures.
Biosafety Level 1
Disease TNM stage IIIA, grade 2,primary ductal carcinoma
Age 48 years adult
Gender female
Ethnicity Black
Applications
HCC2157 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER -), but positive for expression of progesterone receptor (PR +).
The cells are positive for expression of Her2-neu and for expression of p53.
The cells form ducts and morula-like structures (hollow spherical structures lined with a single layer of cells).
Storage Conditions liquid nitrogen vapor temperature
Karyotype Number of cells examined = 59; Modal Chromosome Number = 75 with a range of 65 to 79; Polyploidy Rate = 22%
Derivation
This cell line was initiated on 3/4/96 and took 8 months to establish.
An EBV transformed lymphoblastoid cell line (HCC2157 BL) from the same patient is available as ATCC CRL-2341.
Clinical Data
Black
female
48 years

Receptor Expression
estrogen receptor, negative
progesterone receptor, positive
Oncogene her2/neu +, p53 +
Genes Expressed
Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
Comments
The tumor was classified as TNM stage IIIA, grade 2, ductal carcinoma with 1 out of 9 lymph node metastasis.
The cells form ducts and morula-like structures (hollow spherical structures lined with a single layer of cells).
HCC2157 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
An EBV transformed lymphoblastoid cell line (HCC2157 BL) from the same patient is available as ATCC CRL-2341.
Complete Growth Medium ACL-4 medium supplemented with 10% FBS
The base medium for this cell line is ATCC-formulated DMEM: F12 Medium Catalog No. 30-2006. To make the complete growth medium, add the following components to the base medium:
  1. 0.02 mg/ml insulin
  2. 0.01 mg/ml transferrin
  3. 25 nM sodium selenite
  4. 50 nM Hydrocortisone
  5. 1 ng/ml Epidermal Growth Factor (do not filter)
  6. 0.01 mM ethanolamine
  7. 0.01 mM phosphorylethanolamine
  8. 100 pM triiodothyronine
  9. 0.5% (w/v) bovine serum albumin
  10. 10 mM HEPES
  11. 0.5 mM sodium pyruvate
  12. 2mM L-glutamine(for final conc. of 4.5 mM)
  13. 10% FBS

Subculturing Cultures can be maintained by addition of fresh medium. Cultures grow as floating aggregates of large irregular cell clusters.

Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density).
Cryopreservation
Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature
Culture Conditions
Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
STR Profile
Amelogenin: X
CSF1PO: 10
D13S317: 12
D16S539: 11
D5S818: 13
D7S820: 10,12
THO1: 8,9
TPOX: 9,11
vWA: 14,18
Name of Depositor AF Gazdar, AK Virmani
Year of Origin 1996
References

Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
Restrictions

The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.

References

Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771